Evaluation Time | Study Treatment (n=tot pts; n=pts>UNL) | Values at Each Time Point | Delta at Each Time Point |
---|---|---|---|

Baseline | Placebo (n=15; n=15) | 124 (12) | - |

CGS (n=12; n=12) | 129 (17) | - | |

Month 3 | Placebo (n=14; n=12) | 125 (14) | 2 (9) |

CGS (n=10; n=7) | 122 (22) | -4 (10) | |

Month 6 | Placebo (n=14; n=12) | 125 (15) | 1 (10) |

CGS (n=10; n=7) | 120 (20) | -6 (8) |

Values are expressed as mean (SD); p=not significant in all comparisons.n=tot pts: number of patients with an abnormal glucose value at baseline and, of these, number of patients whose glucose levels were available after 3 and 6 months.n=pts>UNL: number of patients with a glucose level above UNL at each time point.